Although the precise role of tumoral IDO in human ESCC remains to be elucidated, our findings suggest that blocking IDO activity may provide a potential means of restoring the host antitumor immunity in the treatment of ESCC. This evidence concerns the gene IDO1 and esophageal squamous cell carcinoma.